Detection of active fraction of glycogen synthase kinase 3β in cancer cells by nonradioisotopic in vitro kinase assay

Oncology

Volumn 71, Issue 3-4, 2007, Pages 297-305

  Mai, Wei ^a   Miyashita, Katsuyoshi ^a   Shakoori, Abbas ^a   Zhang, Bin ^a,c   Yu, Zhi Wei ^a   Takahashi, Yutaka ^a   Motoo, Yoshiharu ^b   Kawakami, Kazuyuki ^a   Minamoto, Toshinari ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Colon cancer; Glycogen synthase kinase 3 ; Liver cancer; Nonradioisotopic in vitro kinase assay; Pancreas cancer; Stomach cancer

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHOTRANSFERASE; SERINE;

ARTICLE; CANCER CELL CULTURE; CELL LYSATE; CELL STRAIN HEK293; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN VITRO STUDY; LIVER CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; STOMACH CANCER;

BIOLOGICAL ASSAY; CELL LINE, TUMOR; DIGESTIVE SYSTEM NEOPLASMS; GLYCOGEN SYNTHASE KINASE 3; HUMANS;

EID: 34548105655     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000106429     Document Type: Article

References (40)

1. Harwood AJ: Regulation of GSK-3: a cellular multiprocessor. Cell 2001;105:821-824.
2. Doble BW, Woodgett JR: GSK3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003;116:1175-1186.
3. Jope RS, Johnson GVW: The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004;29:95-102.
4. Annaert W, De Strooper B: A cell biological perspective on Alzheimer's disease. Annu Rev Cell Dev Biol 2002;18:25-51.
5. Bhat RV, Budd SL: GSK3β signalling: casting a wide net in Alzheimer's disease. Neurosignals 2002;11:251-261.
6. Eldar-Finkelman H, Krebs EG: Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. Proc Natl Acad Sci USA 1997;94:9660-9664.
7. Cohen P: Identification of a protein kinase cascade of major importance in insulin signal transduction. Philos Trans R Soc Lond Biol Sci 1999;354:485-495.
8. Nikoulina SE, Ciaraldi TP, Mudaliar S, Mohideen P, Carter L, Henry RR: Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes 2000;49:263-271.
9. Cohen P, Goedert M: GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 2004;3:479-487.
10. Meijer L, Flajolet M, Greengard P: Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci 2004;25:471-480.
11. Kypta RM: GSK-3 inhibitors and their potential in the treatment of Alzheimer's disease. Expert Opin Ther Pat 2005;15:1315-1331.
12. Manoukian AS, Woodgett JR: Role of GSK-3 in cancer: regulation by Wnts and other signaling pathways. Adv Cancer Res 2002;84:203-209.
13. Polakis P: The oncogenic activation of β-catenin. Curr Opin Genet Dev 1999;9:15-21.
14. Bienz M, Clevers H: Linking colorectal cancer to Wnt signaling. Cell 2000;103:311-320.
15. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR: Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature 2000;406:86-90.
16. Schwabe RF, Brenner DA: Role of glycogen synthase kinase-3 in TNF-induced NF-κB activation and apoptosis in hepatocytes. Am J Physiol Gastrointest Liver Physiol 2002;283:G204-G211.
17. Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, Billadeau DD, Mai M, Takahashi Y, Minamoto T: Deregulated GSK3β activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun 2005;334:1365-1373.
18. Ghosh JC, Altieri DC: Activation of p53-dependent apoptosis by acute ablation of glycogen synthase kinase-3β in colorectal cancer cells. Clin Cancer Res 2005;11:4580-4588.
19. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD: Glycogen synthase kinase-3β participates in nuclear factor κB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 2005;65:2076-2081.
20. Coghlan MP, Culbert AA, Cross DAE, Corcoran SL, Yates JW, Pearce NJ, Rausch OL, Murphy GJ, Carter PS, Cox LR, Mills D, Brown MJ, Haigh D, Ward RW, Smith DG, Murray KJ, Reith AD, Holder JC: Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 2000;7:793-803.
21. Gayet J, Zhou XP, Duval A, Rolland S, Hoang JM, Cottu P, Hamelin R: Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines. Oncogene 2001;20:5025-5032.
22. Ougolkov A, Zhang B, Yamashita K, Bilim V, Mai M, Fuchs SY, Minamoto T: Associations among β-TrCP, an E3 ubiquitin ligase receptor, β-catenin and NF-κB in colorectal cancer. J Natl Cancer Inst 2004;96:1161-1170.
23. Cross DAE, Culbert AA, Chalmers KA, Facci L, Skaper SD, Reith AD: Selective smallmolecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J Neurochem 2001;77:94-102.
24. Bhat R, Xue Y, Berg S, Hellberg S, Ormö M, Nilsson Y, Radesäter AC, Jerning E, Markgren PO, Borgegård T, Nylöf M, Giménez-Cassina A, Hernández F, Lucas JJ, Díaz-Nido J, Avila J: Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 2003;278:45937-45945.
25. Dihlmann S, Klein S, Doeberitz Mv MK: Reduction of β-catenin/T-cell transcription factor signaling by aspirin and indomethacin is caused by an increased stabilization of phosphorylated β-catenin. Mol Cancer Ther 2003;2:509-516.
26. Rask K, Nilsson A, Brännström M, Carlsson P, Hellberg P, Janson PO, Hedin L, Sundfeldt K: Wnt-signaling pathway in ovarian epithelial tumors: increased expression of β-catenin and GSK3β. Br J Cancer 2003;89:1298-1304.
27. Liao X, Zhang L, Thrasher JB, Du J, Li B: Glycogen synthase kinase-3β suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. Mol Cancer Ther 2003;2:1215-1222.
28. Wang L, Lin HK, Hu YC, Xie S, Yang L, Chang C: Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3β in prostate cells. J Biol Chem 2004;279:32444-32452.
29. Morrison JA, Gulley ML, Pathmanathan R, Raab-Traub N: Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma. Cancer Res 2004;64:5251-5260.
30. Desbois-Mouthon C, Blivet-Van Eggelpoël MJ, Beurel E, Boissan M, Delélo R, Cadoret A, Capeau J: Dysregulation of glycogen synthase kinase-3β signaling in hepatocellular carcinoma cells. Hepatology 2002;36:1528-1536.
31. Pap M, Cooper GM: Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 1998;273:19929-19932.
32. Ougolkov AV, Yamashita K, Mai M, Minamoto T: Oncogenic β-catenin and MMP-7 (matrilysin) cosegregate in late-stage clinical colon cancer. Gastroenterology 2002;122:60-71.
33. Zhang B, Ougolkov A, Yamashita K, Takahashi Y, Mai M, Minamoto T: β-Catenin and ras oncogenes detect most human colorectal cancers. Clin Cancer Res 2003;9:3073-3079.
34. Fuchs SY, Ougolkov AV, Spiegelman VS, Minamoto T: Oncogenic β-catenin signaling networks in colorectal cancer. Cell Cycle 2005;4:1522-1539.
35. Ougolkov A, Yamashita K, Bilim V, Takahashi Y, Mai M, Minamoto T: Abnormal expression of E-cadherin, β-catenin and c-erbB-2 in advanced gastric cancer: its association with liver metastasis. Int J Colorectal Dis 2003;18:160-166.
36. Gerdes B, Ramaswamy A, Simon B, Pietsch T, Bastian D, Kersting M, Moll R, Bartsch D: Analysis of β-catenin mutations in pancreatic tumors. Digestion 1999;60:544-548.
37. Watanabe I, Hasebe T, Sasaki S, Konishi M, Inoue K, Nakagohri T, Oda T, Mukai K, Kinoshita T: Advanced pancreatic ductal cancer: fibrotic focus and β-catenin expression correlate with outcome. Pancreas 2003;26:326-333.
38. Minamoto T, Ougolkov AV, Mai M: Detection of oncogenes in the diagnosis of cancers with active oncogenic signaling. Expert Rev Mol Diagn 2002;2:565-575.
39. Hu FB, Manson JE, Liu S, Hunter D, Colditz GA, Michels KB, Speizer FE, Giovannucci E: Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 1999;91:542-547.
40. Heflin LH, Meyerowitz BE, Hall P, Lichtenstein P, Johansson B, Pedersen NL, Gatz M: Cancer as a risk factor for long-term cognitive deficits and dementia. J Natl Cancer Inst 2005;97:854-856.